First, there were neither any link among survival time and tumor-doubling time, and FGFR3 expression, FGFR3 mutations rate, and p53 expression in the control group nor in the interventional group with high-grade double-negative recurrent BC PDXs. The gene discussed is TP53; the disease is breast cancer.